Whereas most systemic manifestations of rheumatoid arthritis (RA) such as rheumatoid carditis or Felty syndrome have had a decrease in prevalence,1 RA-related interstitial lung disease (ILD) remains a significant cause of morbidity and mortality. Patients with RA-ILD have a 3-fold increase in mortality compared to patients with RA but no ILD, matched for age at RA-ILD onset, sex, and RA duration2; ILD is second only after cardiovascular disease for excess mortality observed in RA.3